AR083926A1 - Derivados de imidazol como inhibidores de la enzima pde10a - Google Patents
Derivados de imidazol como inhibidores de la enzima pde10aInfo
- Publication number
- AR083926A1 AR083926A1 ARP110104313A ARP110104313A AR083926A1 AR 083926 A1 AR083926 A1 AR 083926A1 AR P110104313 A ARP110104313 A AR P110104313A AR P110104313 A ARP110104313 A AR P110104313A AR 083926 A1 AR083926 A1 AR 083926A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkoxy
- methyl
- ethoxy
- Prior art date
Links
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 tetrahydropyran-4-yl-methyl Chemical group 0.000 abstract 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201001045 | 2010-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083926A1 true AR083926A1 (es) | 2013-04-10 |
Family
ID=45217102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104313A AR083926A1 (es) | 2010-11-19 | 2011-11-18 | Derivados de imidazol como inhibidores de la enzima pde10a |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP2640731B9 (https=) |
| JP (1) | JP5937608B2 (https=) |
| KR (1) | KR101916487B1 (https=) |
| CN (1) | CN103328487B (https=) |
| AP (1) | AP3342A (https=) |
| AR (1) | AR083926A1 (https=) |
| AU (1) | AU2011331607B2 (https=) |
| BR (1) | BR112013012378A2 (https=) |
| CA (1) | CA2817663C (https=) |
| CR (1) | CR20130226A (https=) |
| DK (1) | DK2640731T3 (https=) |
| EA (1) | EA027082B1 (https=) |
| EC (1) | ECSP13012698A (https=) |
| ES (1) | ES2547090T3 (https=) |
| GE (1) | GEP20156346B (https=) |
| GT (1) | GT201300130A (https=) |
| HU (1) | HUE025596T2 (https=) |
| JO (1) | JO3089B1 (https=) |
| ME (1) | ME02193B (https=) |
| MY (1) | MY163327A (https=) |
| NZ (1) | NZ610353A (https=) |
| PE (1) | PE20141534A1 (https=) |
| PH (1) | PH12013500968A1 (https=) |
| PL (1) | PL2640731T3 (https=) |
| PT (1) | PT2640731E (https=) |
| RS (1) | RS54210B1 (https=) |
| SG (1) | SG190282A1 (https=) |
| SI (1) | SI2640731T1 (https=) |
| TW (1) | TWI541245B (https=) |
| UA (1) | UA112065C2 (https=) |
| WO (1) | WO2012065612A1 (https=) |
| ZA (1) | ZA201303607B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8552045B2 (en) | 2010-11-19 | 2013-10-08 | H. Lundbeck A/S | Tricyclic imidazole compounds as PDE10 inhibitors |
| CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| WO2013045607A1 (en) * | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013107856A1 (en) * | 2012-01-20 | 2013-07-25 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| RU2644558C2 (ru) * | 2012-06-19 | 2018-02-13 | Сановьон Фармасьютикалз Инк. | Гетероарильные соединения и способы их применения |
| CN103435617B (zh) * | 2013-08-22 | 2016-04-27 | 南京华安药业有限公司 | 一种6,7-二氢-5H-吡咯并[1,2-a]咪唑-2-甲醛的合成方法 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
| MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
| RU2019109039A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств |
| BR112020013820A2 (pt) | 2018-11-06 | 2021-06-01 | H. Lundbeck A/S | inibidores de pde10a para tratamento de sintomas negativos e comprometimentos cognitivos em um paciente sofrendo de esquizofrenia |
| CN109776527A (zh) * | 2019-02-21 | 2019-05-21 | 药雅科技(上海)有限公司 | 一种5-溴-7-氮杂吲哚的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
| RS20050945A (sr) | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| ES2331519T3 (es) | 2003-06-30 | 2010-01-07 | Nycomed Gmbh | Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10. |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| JP2007523152A (ja) | 2004-02-18 | 2007-08-16 | ファイザー・プロダクツ・インク | キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体 |
| WO2005120514A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| UA102693C2 (ru) * | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8133897B2 (en) * | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TW201200516A (en) * | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
-
2011
- 2011-11-14 JO JOP/2011/0339A patent/JO3089B1/ar active
- 2011-11-15 TW TW100141570A patent/TWI541245B/zh not_active IP Right Cessation
- 2011-11-18 CA CA2817663A patent/CA2817663C/en not_active Expired - Fee Related
- 2011-11-18 AP AP2013006928A patent/AP3342A/xx active
- 2011-11-18 SI SI201130586T patent/SI2640731T1/sl unknown
- 2011-11-18 RS RS20150574A patent/RS54210B1/sr unknown
- 2011-11-18 UA UAA201307630A patent/UA112065C2/uk unknown
- 2011-11-18 DK DK11793325.9T patent/DK2640731T3/en active
- 2011-11-18 PT PT117933259T patent/PT2640731E/pt unknown
- 2011-11-18 WO PCT/DK2011/000136 patent/WO2012065612A1/en not_active Ceased
- 2011-11-18 NZ NZ610353A patent/NZ610353A/en not_active IP Right Cessation
- 2011-11-18 EP EP11793325.9A patent/EP2640731B9/en active Active
- 2011-11-18 GE GEAP201113117A patent/GEP20156346B/en unknown
- 2011-11-18 MY MYPI2013001727A patent/MY163327A/en unknown
- 2011-11-18 EA EA201390741A patent/EA027082B1/ru not_active IP Right Cessation
- 2011-11-18 PE PE2013001212A patent/PE20141534A1/es active IP Right Grant
- 2011-11-18 ES ES11793325.9T patent/ES2547090T3/es active Active
- 2011-11-18 ME MEP-2015-130A patent/ME02193B/me unknown
- 2011-11-18 PL PL11793325T patent/PL2640731T3/pl unknown
- 2011-11-18 BR BR112013012378A patent/BR112013012378A2/pt not_active Application Discontinuation
- 2011-11-18 AU AU2011331607A patent/AU2011331607B2/en not_active Ceased
- 2011-11-18 SG SG2013037163A patent/SG190282A1/en unknown
- 2011-11-18 HU HUE11793325A patent/HUE025596T2/en unknown
- 2011-11-18 CN CN201180065325.2A patent/CN103328487B/zh not_active Expired - Fee Related
- 2011-11-18 PH PH1/2013/500968A patent/PH12013500968A1/en unknown
- 2011-11-18 AR ARP110104313A patent/AR083926A1/es unknown
- 2011-11-18 KR KR1020137012797A patent/KR101916487B1/ko not_active Expired - Fee Related
- 2011-11-18 JP JP2013539140A patent/JP5937608B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-16 GT GT201300130A patent/GT201300130A/es unknown
- 2013-05-16 CR CR20130226A patent/CR20130226A/es unknown
- 2013-05-17 ZA ZA2013/03607A patent/ZA201303607B/en unknown
- 2013-06-18 EC ECSP13012698 patent/ECSP13012698A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083926A1 (es) | Derivados de imidazol como inhibidores de la enzima pde10a | |
| AR072199A1 (es) | Derivados de fenilimidazol como inhibidores de la enzima pde10a | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
| AR079498A1 (es) | Derivados de 2-arilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| ECSP12011645A (es) | Compuestos y métodos inhibidores de jak de pirazolopirimidina | |
| CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| PE20121091A1 (es) | Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| PE20060648A1 (es) | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| JP2013536188A5 (https=) | ||
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR064760A1 (es) | Derivados de diazol como inhibidores de la eg-5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |